Comparison of the prognostic predictive value of the TIMI, PAMI, CADILLAC, and GRACE risk scores in STEACS undergoing primary or rescue PCI

Rev Esp Cardiol (Engl Ed). 2012 Mar;65(3):227-33. doi: 10.1016/j.recesp.2011.10.019. Epub 2012 Jan 26.
[Article in English, Spanish]

Abstract

Introduction and objectives: We sought to compare the predictive value of the Thrombolysis In Myocardial Infarction (TIMI), Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC), Primary Angioplasty in Myocardial Infarction (PAMI), and Global Registry for Acute Coronary Events (GRACE) scores for the outcome of ST-segment elevation acute coronary syndrome undergoing urgent percutaneous coronary intervention.

Methods: We performed a retrospective analysis of a cohort composed of all consecutive patients with ST-segment elevation acute coronary syndrome treated by urgent percutaneous coronary intervention between 2006 and 2010 (n=1503). TIMI, PAMI, CADILLAC, and GRACE risk scores were calculated for each patient according to different clinical variables. We assessed the predictive accuracy of these scores for death, reinfarction, and target-vessel revascularization at 30 days and 1 year, using the C statistic, which was obtained by means of logistic regression and ROC curves.

Results: The TIMI, PAMI, CADILLAC and GRACE showed an excellent predictive value for 30-day and 1-year mortality (C statistic range, 0.8-0.9), with superiority of the TIMI, CADILLAC, and GRACE risk models. The performance of these 4 scores was poor for both reinfarction and target-vessel revascularization (C statistic, 0.5-0.6).

Conclusions: The TIMI, PAMI, CADILLAC, and GRACE scores provide excellent information to stratify the risk of mortality in patients treated by percutaneous coronary intervention. The TIMI, CADILLAC, and GRACE models have higher predictive accuracy. The usefulness of these models for reinfarction and target-vessel revascularization prediction is questionable.

Publication types

  • Comparative Study

MeSH terms

  • Abciximab
  • Acute Coronary Syndrome / surgery
  • Aged
  • Angioplasty, Balloon, Coronary*
  • Antibodies, Monoclonal / therapeutic use*
  • Cohort Studies
  • Coronary Disease / complications
  • Coronary Disease / mortality
  • Coronary Disease / surgery*
  • Female
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use*
  • Logistic Models
  • Male
  • Middle Aged
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / surgery*
  • Myocardial Revascularization
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Postoperative Complications / drug therapy*
  • Postoperative Complications / mortality
  • Predictive Value of Tests
  • Prognosis
  • ROC Curve
  • Recurrence
  • Registries
  • Retrospective Studies
  • Risk Assessment
  • Thrombolytic Therapy*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Abciximab